Colorectal Cancer Metastatic MSI-High Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Micros

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Colorectal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer. 2. No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass. 3. Tumor determined to be mismatch-repair deficient (dMMR) or MSI-H

You may not be eligible for this study if the following are true:

  • 1. Patients with CNS metastases 2. Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin 3. Uncontrolled high blood pressure

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.